CJC-1295 No DAC + Ipamorelin Dosage & Mixing Guide

CJC-1295 (NO DAC) + Ipamorelin

CJC-1295 (No DAC) and Ipamorelin are commonly paired in growth-hormone-axis research because they act through different signaling pathways. CJC-1295 (No DAC), often referred to as modified GRF (1-29), targets the GHRH receptor pathway, while Ipamorelin acts through the ghrelin/GHS receptor pathway. The specific combination has not been established as a standardized human clinical protocol.

How It Works

GHRH-Receptor Signaling + Ghrelin-Receptor Signaling → GH-Axis Research → Potential Downstream IGF-1 Signaling

The rationale for pairing the compounds is complementary receptor signaling: CJC-1295 (No DAC) is associated with GHRH-receptor activation, while Ipamorelin is a growth-hormone secretagogue acting through the ghrelin/GHS receptor. Although the mechanistic rationale for complementary GH signaling exists, the specific combination has not been validated in controlled human clinical trials.

Blended Vial Research-Use Framework

5 mg CJC-1295 + 5 mg Ipamorelin → 3.0 mL BAC Water → 1 unit = 16.7 mcg of each peptide

Example Research-Use Schedule

Frequency Once daily

Example Timing Evening / bedtime

Route Subcutaneous

Research-Use Cycle 8–12 weeks

How to read the protocol below:
The dose shown for each phase represents the amount used once per day in this example research-use framework. The separate split-dose section shows a different morning + evening structure.

Blended Vial Setup

Blend5 mg CJC-1295 + 5 mg Ipamorelin

Water3.0 mL

Concentration1.67 mg/mL each peptide

Conversion1 unit = 16.7 mcg CJC-1295 + 16.7 mcg Ipamorelin

Combined1 unit = about 33 mcg total

Weeks 1–2

Starting Phase

Dose100 mcg of each peptide

Combined Total200 mcg total

Units6 units total

Volume0.06 mL

Weeks 3–4

Build Phase

Dose150 mcg of each peptide

Combined Total300 mcg total

Units9 units total

Volume0.09 mL

Weeks 5–8

Full Research-Use Phase

Dose200 mcg of each peptide

Combined Total400 mcg total

Units12 units total

Volume0.12 mL

Weeks 9–12

Extended Research-Use Phase

Dose250 mcg of each peptide

Combined Total500 mcg total

Units15 units total

Volume0.15 mL

Evidence Note:
The dosing progression shown here is a research-use framework rather than a clinically validated protocol. Published human CJC-1295 research primarily involves the long-acting DAC form, and direct human evidence for CJC-1295 (No DAC) combined with Ipamorelin is lacking.
Why use blended?

Simple Option

This is the simplest option. Both peptides are delivered together in one syringe with one draw and one injection.

Best For

A blended vial provides one-syringe convenience and simpler unit calculations, but both compounds remain locked into the same ratio.

Separate Vials Research-Use Framework (Flexible)

CJC-1295 = GHRH Support → Ipamorelin = Ghrelin Receptor Support → Flexible Timing with the Same Target Doses

Example Research-Use Schedule

Frequency Once daily

Example Timing Evening / bedtime

Route Subcutaneous

Research-Use Cycle 8–12 weeks

How to read the protocol below:
The dose shown for each phase represents the amount of each peptide used once per day in this example research-use framework. Separate vials allow the amount of CJC-1295 (No DAC) and Ipamorelin to be calculated and adjusted independently.

Separate Vials Setup

Based on 5 mg vials for each peptide

CJC-12955 mg vial + 3.0 mL BAC water

Ipamorelin5 mg vial + 3.0 mL BAC water

CJC Conversion1 unit = 16.7 mcg

Ipamorelin Conversion1 unit = 16.7 mcg

Weeks 1–2

Starting Phase

CJC-12956 units (100 mcg)

Ipamorelin6 units (100 mcg)

Total Drawn12 units total

Combined Total200 mcg total

Volume0.12 mL

Weeks 3–4

Build Phase

CJC-12959 units (150 mcg)

Ipamorelin9 units (150 mcg)

Total Drawn18 units total

Combined Total300 mcg total

Volume0.18 mL

Weeks 5–8

Full Research-Use Phase

CJC-129512 units (200 mcg)

Ipamorelin12 units (200 mcg)

Total Drawn24 units total

Combined Total400 mcg total

Volume0.24 mL

Weeks 9–12

Extended Research-Use Phase

CJC-129515 units (250 mcg)

Ipamorelin15 units (250 mcg)

Total Drawn30 units total

Combined Total500 mcg total

Volume0.30 mL

Why use separate vials?

More Control

This setup gives you more control. You can still match the same standard doses, but you can also change the schedule later if you want to adjust one peptide without changing the other.

Best For

Useful when you want flexibility and future control.

Split-Dose Research-Use Framework Protocol

Morning + Evening Administration → More Frequent Exposure → Different GH-Axis Research Pattern

Main Example Once daily

Example Timing Evening / bedtime

Split-Dose Example Twice daily — morning + evening

Injection Type Subcutaneous

Research-Use Cycle 8–12 weeks

Commonly Discussed Break 2–4 weeks

Weeks 1–2

Starting Phase

Morning50 mcg CJC + 50 mcg Ipamorelin

Night100 mcg CJC + 100 mcg Ipamorelin

Daily Total150 mcg each

Weeks 3–4

Build Phase

Morning100 mcg CJC + 100 mcg Ipamorelin

Night100 mcg CJC + 100 mcg Ipamorelin

Daily Total200 mcg each

Weeks 5–8

Full Research-Use Phase

Morning100 mcg CJC + 100 mcg Ipamorelin

Night150 mcg CJC + 150 mcg Ipamorelin

Daily Total250 mcg each

Weeks 9–12

Extended Research-Use Phase

Morning150 mcg CJC + 150 mcg Ipamorelin

Night150 mcg CJC + 150 mcg Ipamorelin

Daily Total300 mcg each

Research-Use Rationale:
Split dosing is discussed as a way to create more than one daily exposure period. However, controlled human studies have not established that twice-daily CJC-1295 (No DAC) + Ipamorelin better reproduces physiologic GH rhythms or produces superior outcomes.

How to Use CJC-1295 (NO DAC) + Ipamorelin

Research-Use Cycle8–12 weeks

Commonly Discussed Break2–4 weeks off

Clinical StandardNo standardized cycle or required off-period has been established

Injection TypeSubcutaneous in the research-use framework shown

Use StyleBlended, separate, or split dosing

Best Time to Take

Most commonly used 30–60 minutes before bed

Split-dose protocols often use a fasted morning dose plus a bedtime dose

Consistency matters more than chasing perfect timing

Where to Inject

Abdomen, thigh, or upper arm

Rotate injection sites regularly

Separate-vial users often draw both into one syringe

Food Timing Considerations

Before InjectionAvoid eating for 2–3 hours before

After InjectionWait 20–30 minutes before eating

WhyInsulin and elevated blood sugar can reduce the GH pulse

CJC-1295 (NO DAC) and Ipamorelin are commonly used in a fasted state because growth hormone release is stronger when insulin is low.

Eating carbohydrates or a full meal too close to your injection may blunt the intended GH response.

A common simple rule is: inject when fasted, then wait about 20–30 minutes before eating.

Meal timing is frequently discussed in GH-secretagogue research-use protocols because glucose, insulin, nutritional state, and GH secretion interact physiologically. However, a specific 2–3 hour fast before and 20–30 minute fast after CJC-1295 (No DAC) + Ipamorelin has not been established as a clinically validated requirement.

Areas of Research Interest

Growth-hormone-axis and secretagogue research

GHRH and ghrelin-receptor signaling research

GH pulsatility and downstream IGF-1 signaling research

Recovery and body-composition research contexts

Comparison of blended, separate, and split-dose research frameworks

Reconstitution & Dosing

Blended Vial Reconstitution

Blend5 mg CJC-1295 + 5 mg Ipamorelin

Water3.0 mL total

Concentration1.67 mg/mL each

Conversion1 unit = 16.7 mcg CJC + 16.7 mcg Ipamorelin

Steps

Draw 3.0 mL bacteriostatic water

Inject slowly down the vial wall

Gently swirl, do not shake

Allow powder to fully dissolve before use

Refrigerate after reconstitution

Use within about 4 weeks after mixing

Separate Vials Reconstitution

CJC-12955 mg vial

Ipamorelin5 mg vial

Water3.0 mL into each vial

CJC Conversion1 unit = 16.7 mcg

Ipamorelin Conversion1 unit = 16.7 mcg

Steps

Draw 3.0 mL bacteriostatic water into the CJC-1295 vial

Draw 3.0 mL bacteriostatic water into the Ipamorelin vial

Inject slowly down each vial wall

Gently swirl each vial, do not shake

Refrigerate both vials after mixing

Use within about 4 weeks after reconstitution

Blended vs Separate (Which Should You Use?)

Blended Vial

Best for simplicity and convenience

Both peptides follow the same timing and dose progression

Easy math and beginner-friendly structure

Separate Vials

Best if you want more control later

Lets you adjust one peptide independently if needed

Useful if your source sells them separately

Simple takeaway:
Choose blended if you want simplicity. Choose separate if you want flexibility and future control.

Storage & Shelf Life

Storage & Shelf Life

Lyophilized (unmixed)

Refrigerated (2–8°C): ~12–24 months

Frozen (−20°C): up to ~2–3 years

Reconstituted (mixed)

Refrigerated (2–8°C): ~30 days typical use window

Do not freeze after mixing

Blended vs Separate Storage

Blended Vial

Both peptides share the same solution, so storage and stability are tied together.

Separate Vials

Separate vials can give you slightly more flexibility with handling and preservation.

Best Practice

Handling

Keep vials cold and protected from light.

Temperature

Avoid repeated temperature changes.

Visual Check

If solution becomes cloudy, discolored, or has particles, discard.

Time Between Cycles

Standard Time Between Cycles

Cycle Length8–12 weeks

Time Off2–4 weeks

Why take a break?
CJC-1295 (NO DAC) + Ipamorelin is usually run in defined GH support phases rather than continuously. Taking time off helps reassess response and keeps the protocol more purpose-driven.

When to Stop Sooner

Sleep, recovery, or body composition benefits feel flat

The main goal phase has ended

Meal timing discipline is slipping and the protocol is no longer being used as intended

Monitoring During Use

Injection-site tolerance

Any new or unexpected symptoms

Changes relevant to the defined research goal

IGF-1 and metabolic markers when clinically appropriate

Overall response to the combined GH-axis research framework

Benefits

Combines two compounds associated with complementary GH-axis signaling pathways

CJC-1295 (No DAC) targets GHRH-receptor signaling

Ipamorelin acts through the ghrelin / growth-hormone secretagogue receptor pathway

GH and IGF-1 signaling are involved in body composition, tissue metabolism, and recovery physiology

Clinical benefits of the specific CJC-1295 (No DAC) + Ipamorelin combination have not been established in controlled human trials

Potential Side Effects

Injection-site irritation may occur

Headache, flushing, hunger changes, or fluid retention may occur with GH-axis secretagogue use

Changes in glucose regulation are a relevant consideration with increased GH / IGF-1 signaling

Human safety data for the specific CJC-1295 (No DAC) + Ipamorelin combination are limited

Long-term safety of repeated combined use has not been established

Stacking Strategies

GH Pulse ↑ → IGF-1 ↑ → Recovery + Body Composition Support

Recovery: Add BPC-157

Body Composition: Pair with disciplined sleep, training, and nutrition

Simple takeaway:
CJC-1295 (No DAC) + Ipamorelin already combines two GH-axis compounds. Adding additional GHRH analogs, GH secretagogues, MK-677, or IGF-1–pathway compounds increases pathway overlap and should not be presented as a routine stacking strategy.

Important Notes

CJC-1295 (No DAC) and Ipamorelin act through different GH-axis signaling pathways, which provides the mechanistic rationale for pairing them.

The specific CJC-1295 (No DAC) + Ipamorelin combination has not been validated as a standardized human clinical protocol.

Human CJC-1295 research should not be generalized between DAC and No-DAC formulations; the best-known human clinical research evaluated long-acting CJC-1295 with DAC.

Blended and separate formulations can provide equivalent peptide amounts when concentrations are matched, but separate vials allow each component to be adjusted independently.

Adding other GH secretagogues, GHRH analogs, or IGF-1-pathway compounds can create substantial pathway overlap.

Important Disclaimer

CJC-1295 (NO DAC) and Ipamorelin are not FDA-approved and are intended for research purposes only.

Research & References

Primary Research

• Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
• Ionescu M, Frohman LA. Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. Journal of Clinical Endocrinology & Metabolism. 2006.
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
• Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 1999.

CJC-1295 (NO DAC) + Ipamorelin Stack Guide → Peptide Directory →